ADT1236-Faricimab Biosimilar-Anti-ANGPT2/VEGFA mAb-Research Grade

Catalog Number

ADT1236

Product Name

ADT1236-Faricimab Biosimilar-Anti-ANGPT2/VEGFA mAb-Research Grade

Clonity

Monoclonal

Alternate Names

anti-mouse ANGPT2 antibody,  anti-ANGPT2 antibody,  anti ANGPT2 antibody,  recombinant ANGPT2,  ANGPT2 antibody,  anti-ANGPT2 monoclonal antibody,  ANGPT2 antibodies,  ANGPT2 recombinant antibody,  ANGPT2 blocking antibody,  VEGFA recombinant antibody,  VEGFA blocking antibody

Alias

RG7716,  RO6867461

Host

CHO Cells

Species

Human

Target

IgG1 Kappa Lambda

Gene ID

285

Isotype

VH-C Kappa-CH2-CH3_V Lambda-CH1_H-GAMMA-1_L Kappa

Size

1mg, 5mg

Research Area

Immunology

CAS Number

1607793-29-2

Product Description

Faricimab (INN) is a bispecific monoclonal antibody that is being investigated for diabetic macular edema. This drug is being developed by Hoffmann-La Roche. As of 2018,  faricimab is undergoing Phase III trials.

Mechanism of Action

The retina is largely avascular to facilitate effective photoreceptor function; rather,  the retina is fed by both retinal and choroidal capillary networks,  pathologies of which result in retinal and choroidal vascular diseases such as diabetic macular edema (DME),  age-related macular degeneration (AMD),  and retinal vein occlusion (RVO). One of the underlying causes of retinal vascular diseases (RVDs) is retinal neovascularization (NV),  the aberrant growth of new vasculature,  usually due to sustained retinal ischemia and mediated primarily by vascular endothelial growth factor A (VEGF-A). VEGF-A is a VEGF family member,  which also includes VEGF-B,  -C,  and -D,  whose members signal through the VEGF receptors (VEGFRs) VEGFR-1,  -2,  and -3 to mediate endothelial and lymphatic growth. Extensive work in animal models of RVD has demonstrated that VEGF-A is necessary but not sufficient in many cases to mediate NV,  suggesting that additional factors may be required in deep retinal capillary beds. One such factor has been identified as the angiopoietins Ang-1 and Ang-2 and their cellular receptor Tie-2; Ang-1 is a full Tie-2 agonist whose binding results in Tie-2 phosphorylation and downstream signalling,  whereas Ang-2 is a Tie-2 partial agonist/antagonist that Inhibitionits Tie-2 phosphorylation. Ang-1 generally has a protective effect,  making endothelial cells less responsive to VEGF-A,  while Ang-2 increases VEGF-A-dependent NV and stimulates pericyte apoptosis and breakdown of both the blood-brain and blood-retinal barriers; Ang-2 is upregulated in retinal vascular development and retinal ischemia.

Metabolism

Faricimab has a long half-life and is distributed throughout the bloodstream and tissues.

Molecular Weight

149.00 KDa

Application

Elisa,  WB

Purity

>95% as determined by SDS-PAGE

Concentration

batch dependent

Buffer

Supplied in PBS,  PH7.5

Storage

Store at -20 °C for 12 months. Store at -80 °C for long term storage.

Shipping Condition

Shipped on ice packs.

Note

This product is for research use only.

Reactivity

Human

Reference